ADMA Biologics, Inc. (ADMA)

ADMA Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	426.45	258.22	154.08	80.94	42.22
Revenue Growth (YoY)	65.16%	67.58%	90.36%	91.72%	43.85%
Cost of Revenue	206.9	167.17	118.82	79.77	53.79
Gross Profit	219.55	91.04	35.27	1.17	-11.57
Selling, General & Admin	78.37	62.59	70.3	55.19	39.22
Research & Development	1.81	3.3	3.61	2.85	5.91
Operating Expenses	80.57	66.61	74.63	58.75	45.84
Operating Income	138.98	24.43	-39.37	-57.57	-57.41
Interest Expense	-13.93	-25.03	-19.28	-13.06	-11.99
Interest & Investment Income	2.1	1.62	0.05	0.04	0.29
Other Non Operating Income (Expenses)	-0.19	-0.29	-0.64	-0.25	-0.13
EBT Excluding Unusual Items	126.96	0.74	-59.23	-70.85	-69.24
Merger & Restructuring Charges	-	-	-	-	-7.5
Asset Writedown	-	-2.1	-	-	-
Other Unusual Items	-1.24	-26.87	-6.67	-0.8	0.99
Pretax Income	125.71	-28.24	-65.9	-71.65	-75.75
Income Tax Expense	-71.96	-	-	-	-
Net Income	197.67	-28.24	-65.9	-71.65	-75.75
Net Income to Common	197.67	-28.24	-65.9	-71.65	-75.75
Shares Outstanding (Basic)	233	224	198	140	86
Shares Outstanding (Diluted)	243	224	198	140	86
Shares Change (YoY)	8.65%	13.19%	41.77%	62.03%	58.51%
EPS (Basic)	0.85	-0.13	-0.33	-0.51	-0.88
EPS (Diluted)	0.81	-0.13	-0.33	-0.51	-0.88
Free Cash Flow	110.45	4.03	-73.42	-125.88	-114.73
Free Cash Flow Per Share	0.45	0.02	-0.37	-0.90	-1.33
Gross Margin	51.48%	35.26%	22.89%	1.45%	-27.41%
Operating Margin	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Profit Margin	46.35%	-10.94%	-42.77%	-88.52%	-179.41%
Free Cash Flow Margin	25.90%	1.56%	-47.65%	-155.52%	-271.74%
EBITDA	147.03	32.76	-32.25	-52.08	-53.47
EBITDA Margin	34.48%	12.69%	-20.93%	-64.34%	-126.65%
D&A For EBITDA	8.05	8.33	7.11	5.5	3.94
EBIT	138.98	24.43	-39.37	-57.57	-57.41
EBIT Margin	32.59%	9.46%	-25.55%	-71.13%	-135.99%
Revenue as Reported	-	-	-	-	42.22

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q